Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 December 2022 | Story Lacea Loader | Photo Supplied
Prof Mogomme Masoga
Prof Mogomme Masoga, newly appointed Dean: Faculty of the Humanities.

The Council of the University of the Free State (UFS) approved the appointment of Prof Mogomme Masoga as Dean of the Faculty of the Humanities for a five-year term during its quarterly meeting on 25 November 2022. 

He is currently the Dean of the Faculty of Humanities and Social Sciences at the University of Zululand. 

“Prof Masoga has extensive and an impressive national and international research standing, established networks and partnerships, and substantive management experience. He is a visionary leader and a renowned scholar and will be able to lead and manage the faculty at academic, research, engaged scholarship, and community-service level,” says Prof Francis Petersen, UFS Rector and Vice-Chancellor. 

Prof Masoga holds a PhD in Philosophy from the University of the Free State. He began his academic career with a Bachelor of Arts from the University of KwaZulu-Natal, where he proceeded to complete two honours and a master’s degree. He received a second Master of Arts in Musicology from the University of South Africa.

Prof Masoga has an excellent record of research publication within the broad niche area of Oral History, Africanism, and Indigenous Knowledge System Studies. He has developed a well-grounded sense of autonomy and involvement, as he has been able to establish a number of research projects and has produced single and co-authored articles. He was able to synergise and sustain his research niche on Africanism and Indigenous Knowledge Studies, which has informed his research over the years. 

He has maintained a coherent research trajectory as a recognised NRF-rated scholar in Indigenous Knowledge System Studies. Prof Masoga’s participation in international collaborative projects has had a positive impact on his scholarly growth, as well as on other colleagues and departments in his faculty at the University of Zululand. 

“Prof Masoga will be able to sustain his existing networks and build new ones that will support research and postgraduate studies at the UFS. This will be particularly valuable in support of the university’s Vision 130, which expresses the institution’s strategic intent to position itself in the period leading up to 2034 when the university will be 130 years old. Vision 130 furthermore exemplifies our commitment to be acknowledged by our peers and society as a top-tier university in South Africa, ranked among the best in the world,” says Prof Petersen. 

Prof Masoga will assume duty on 1 March 2023.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept